Tools   Select Another Resource Report Type

http://www.allosource.org/

AlloSource is a non-profit organization founded in 1994 on a promise to honor and respect the gift of donation by responsibly developing, processing and distributing life-saving and life-enhancing allografts for our communities. Today, each of our 300 employees continues to fulfill this promise through multi-shift, 360-day processing to the highest quality and service standards. We strive to be the tissue network patients and the world''s most respected transplant teams ask for by name. This is accomplished by understanding the needs of our doctors and by providing the best tissue for our recipients. We offer more than 200 standard and customized precision allograft products, and act as a trusted and knowledgeable partner to the medical community, all with the intention of maximizing medical impact. In 1995, Allosource evolved from a local tissue bank in Denver, Colorado into a national organization serving communities around the country. Today, AlloSource is one of the largest, most respected tissue banks in the United States. Through our growth we''ve remained committed to the wishes of donor families, the needs of our surgeon customers, and the hopes of our patient recipients. Our promise of doing more with life reflects our unwavering focus on integrity, quality, safety, and respect today, and into the future.

Proper citation: AlloSource (RRID:SCR_010683) Copy   

•   Source: SciCrunch Registry

http://www.origene.com/

A research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene''s vision is to prepare comprehensive, genome wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Their flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collection and over 25,000 TrueORF cDNA clones. From their TrueORF cDNA clones, they have developed the largest offering of full length human proteins expressed in mammalian cells, ideal for functional studies. Their TrueMAB project develops mouse monoclonal antibodies against protein antigens with the goal to develop protein assays for every human protein. They also offer complete molecular biology services from codon optimization, gene synthesis, protein expression and assay development. In addition, they offer unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation.

Proper citation: OriGene (RRID:SCR_008985) Copy   

•   Source: SciCrunch Registry

https://www.nimhgenetics.org/

Collaborative venture between the National Institute of Mental Health (NIMH) and several academic institutions. Repository facilitates psychiatric genetic research by providing patient and control samples and phenotypic data for wide-range of mental disorders and Stem Cells.Stores biosamples, genetic, pedigree and clinical data collected in designated NIMH-funded human subject studies. RGR database likewise links to other repositories holding data from same subjects, including dbGAP, GEO and NDAR. Allows to access these data and biospecimens (e.g., lymphoblastoid cell lines, induced pluripotent cell lines, fibroblasts) and further expand genetic and molecular characterization of patient populations with severe mental illness.

Proper citation: NIMH Repository and Genomics Resources (RRID:SCR_006698) Copy   

•   Source: SciCrunch Registry

http://www.osiris.com/

Stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. Now part of Smith and Nephew.

Proper citation: Osiris Therapeutics (RRID:SCR_004233) Copy   

•   Source: SciCrunch Registry

http://www.jax.org/index.html

An independent, nonprofit organization focused on mammalian genetics research to advance human health. Their mission is to discover the genetic basis for preventing, treating, and curing human disease, and to enable research for the global biomedical community. Jackson Laboratory breeds and manages colonies of mice as resources for other research institutions and laboratories, along with providing software and techniques. Jackson Lab also conducts genetic research and provides educational material for various educational levels.

Proper citation: Jackson Laboratory (RRID:SCR_004633) Copy   

•   Source: SciCrunch Registry

http://www.hema-quebec.qc.ca/index.en.html

Hema-Quebec''s mission is to efficiently provide adequate quantities of safe, optimal blood components, substitutes, human tissues and cord blood to meet the needs of all Quebecers; provide and develop expertise along with specialized and innovative services and products in the fields of transfusion medicine and human tissue transplantation. Hema-Quebec is driven by the commitment, support and recognition of its employees as well as the trust of its partners to remain the standard of quality and innovation with respect to the safe procurement of blood products, human tissues and stem cells.

Proper citation: Hema-Quebec (RRID:SCR_004700) Copy   

•   Source: SciCrunch Registry

http://www.bari2d.org/

A multicenter randomized clinical trial that aims to determine the best therapies for people with type 2 diabetes and moderately severe cardiovascular disease. 2368 participants were randomized at 49 sites in 6 countries. All subjects were given intensive medical therapy to control cholesterol and blood pressure and given counseling, if needed, to quit smoking and to lose weight. Beyond that, they compared whether prompt revascularization, either bypass surgery or angioplasty, e.g. stents, was more effective than medical therapy alone. At the same time, they also looked at which of two diabetes treatment strategies resulted in better outcomes����??insulin-providing versus insulin-sensitizing - that is, increasing the amount of insulin or making the insulin work better. Only patients with known type 2 diabetes and heart disease that could be treated appropriately with a revascularization OR medical therapy alone were eligible for the trial. Patients entered the study between January 2001 ����?? March 2005 and were followed for an average of five years. When a patient entered the study, physicians first decided whether that patient should receive stenting or bypass surgery. The patient then received their randomization assignment. All patients were treated in BARI 2D for both their diabetes and heart disease, as well as other risk factors that might effect those diseases, regardless of which group they were in. Diabetes-specific complications including retinopathy, nephropathy, neuropathy, and peripheral vascular disease were monitored regularly. Tests, blood samples, urine samples, and treatment cost data were obtained periodically through the trial and examined by experts at 7 central laboratories and other research partners. Experts on risk factors routinely oversaw treatments of all patients at 4 central management centers. A panel of independent experts reviewed data every six months to make sure that all patients were receiving safe care.

Proper citation: BARI 2D (RRID:SCR_001496) Copy   

•   Source: SciCrunch Registry

http://www.atcc.org/

Global nonprofit biological resource center (BRC) and research organization that provides biological products, technical services and educational programs to private industry, government and academic organizations. Its mission is to acquire, authenticate, preserve, develop and distribute biological materials, information, technology, intellectual property and standards for the advancement and application of scientific knowledge. The primary purpose of ATCC is to use its resources and experience as a BRC to become the world leader in standard biological reference materials management, intellectual property resource management and translational research as applied to biomaterial development, standardization and certification. ATCC characterizes cell lines, bacteria, viruses, fungi and protozoa, as well as develops and evaluates assays and techniques for validating research resources and preserving and distributing biological materials to the public and private sector research communities.

Proper citation: ATCC (RRID:SCR_001672) Copy   

•   Source: SciCrunch Registry

http://roslincells.com/

Organization that supplies undifferentiated, clinical grade, human pluripotent stem cell lines to the life science community, and works with academic, clinical and commercial colleagues to enable and facilitate the use of these high grade cells in the development of new reagents, drugs and cellular therapeutics. They also seek to drive the economic development of the stem cell sector in Scotland. Their products can act as a valuable tool in supporting clients' drug discovery, development and clinical research programmes.

Proper citation: Roslin Cells (RRID:SCR_003857) Copy   

•   Source: SciCrunch Registry

http://www.endocells.fr/?lang=en

This resource no longer in service. Documented on August 12, 2021. French biotech company dedicated to human endocrine cell line production with a first focus on human pancreatic beta cell. Other cell types are being prepared like glucagon cells. The material will be powerful tools for drug discovery, toxicology and cell replacement therapy. Achievements to date * Generated tumoral and non-tumoral human beta cell lines which closely resemble human primary pancreatic beta cells (using technologies which have been first developed and validated using immortalized rat beta cell lines). World first. * Established a robust technology platform which will be used to develop other human endocrine cell lines.

Proper citation: Endocells (RRID:SCR_004067) Copy   

•   Source: SciCrunch Registry

http://www.giftofhope.org/

Gift of Hope Organ & Tissue Donor Network is proud to serve as the federally designated not-for-profit agency that coordinates organ and tissue donation and supports families of donors in the northern three-quarters of Illinois and northwest Indiana. Since our inception in 1986, we have coordinated donations that have saved the lives of 17,000 organ transplant recipients and helped hundreds of thousands of other patients receive needed tissue transplants. As one of 58 organ procurement organizations (OPOs) that make up the nation''s organ donation system, we work with 179 hospitals in our donation service area. In managing the recovery, care and transportation of donated organs to transplant patients, we work closely with Illinois'' nine transplant centers, which operate 32 transplant programs. We also work with other transplant centers and other OPOs through the United Network for Organ Sharing (UNOS) to provide lifesaving organs for patients awaiting them. UNOS is the federally mandated registration center for organ transplant candidates in the United States. UNOS'' computer-based system matches donated organs with patients in need, in accordance with strict federal guidelines intended to ensure equitable distribution.

Proper citation: Gift of Hope Organ and Tissue Donor Network (RRID:SCR_004968) Copy   

•   Source: SciCrunch Registry

http://www.lifelegacy.org

A non-profit tissue bank that facilitates the distribution of non-transplantable tissue to the medical and research community. It provides snap frozen low post mortem interval (PMI) tissue, normal and diseased tissue, plastinated specimens, anatomical specimens, and specialty specimens. The foundation also works to increase public awareness of research tissue donation for medical research.

Proper citation: LifeLegacy Foundation (RRID:SCR_000518) Copy   

•   Source: SciCrunch Registry

http://www.mhasweb.org/

A dataset of a prospective panel study of health and aging in Mexico. The study was designed to ensure comparability with the U.S. Health and Retirement Study in many domains, and the NHANES III. The baseline survey in 2001 is nationally representative of the 13 million Mexicans born prior to 1951. The six Mexican states which are home to 40% of all migrants to the U.S. were over-sampled at a rate of 1.7:1. Spouse/partners of eligible respondents were interviewed also, even if the spouse was born after 1950. Completed interviews were obtained in 9,862 households, for a total of 15,186 individual interviews. All interviews were face-to-face, with average duration of 82 minutes. A direct interview (on the Basic questionnaire) was sought, and Proxy interviews were obtained when poor health or temporary absence precluded a direct interview. Questionnaire topics included the following: * HEALTH MEASURES: self-reports of conditions, symptoms, functional status, hygienic behaviors (e.g., smoking & drinking history), use/source/costs of health care services, depression, pain, reading and cognitive performance; * BACKGROUND: Childhood health and living conditions, education, ability to read/write and count, migration history, marital history; * FAMILY: rosters of all children (including deceased children); for each, demographic attributes, summary indicators of childhood and current health, education, current work status, migration. Parent and sibling migration experiences; * TRANSFERS: financial and time help given to and received by respondent from children, indexed to specific child; time and financial help to parent; * ECONOMIC: sources and amounts of income, including wages, pensions, and government subsidies; type and value of assets. All amount variables are bracketed in case of non-response. * HOUSING ENVIRONMENT: type, location, building materials, other indicators of quality, and ownership of consumer durables; * ANTHROPOMETRIC: for a 20% sub-sample, measured weight, height; waist, hip, and calf circumference; knee height, and timed one-leg stands. Current plans are to conduct another two follow-up surveys in 2012 and 2014 and will field the 3rd and 4th waves of survey data collection in Mexico. For the 2012 wave, interviews will be sought for: every person who was part of the panel in 2003 and their new spouse / partner, if applicable, and a new sample of persons born between 1952 and 1962. For the 2014 wave, we will follow-up the whole sample from 2012. Interviews will be conducted person-to-person. Direct interviews will be sought with all informants, but proxy interviews are allowed for those unable to complete their own interview for health or cognitive reasons. A next-of-kin interview will be completed with a knowledgeable respondent for those who were part of the panel but have died since the last interview. A sub-sample will be selected to obtain objective markers such as blood sample and anthropometric measures. Data Availability: The 2001 baseline data, 2003 follow-up data, and documentation can be downloaded. * Dates of Study: 2001-2003 * Study Features: Longitudinal, International, Anthropometric Measures * Sample Size: 2001: 15,186 (Baseline) Link: * ICPSR: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/00142

Proper citation: Mexican Health and Aging Study (RRID:SCR_000818) Copy   

•   Source: SciCrunch Registry

http://www2.bsc.gwu.edu/bsc/oneproj.php?pkey=28

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 31,2025. Collect, store, and distribute genetic samples from cases and controls of type 1 diabetes and diabetic nephropathy for investigator-driven research into the genetic basis of diabetic nephropathy. As the risk of kidney complications in type 1 diabetes appears to have a considerable genetic component, this study assembled a large data resource for researchers attempting to identify causative genetic variants. The types of data collected allowed traditional case-control testing, a rapid and often powerful approach, and family-based analysis, a robust approach that is not influenced by population substructure.

Proper citation: Genetics of Kidneys in Diabetes (RRID:SCR_000133) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29346&a=31576&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. PRACSIS (Prognosis and Risk in Acute Coronary Syndromes In Sweden) aims to study prognosis and its predictors in a consecutive series of patients with acute coronary syndrome (ACS). The study is comprised of patients between 18 and 80 years diagnosed at the coronary care unit at the Sahlgrenska University Hospital with unstable angina, non-ST-elevation MI or ST-elevation MI. Extensive information on medical history and blood samples for analyses of biochemical markers and genetic factors have been collected.

Proper citation: PRACSIS - Prognosis and Risk in Acute Coronary Syndromes In Sweden (RRID:SCR_000615) Copy   

•   Source: SciCrunch Registry

http://titan.biotec.uiuc.edu/bee/honeybee_project.htm

A database integrating data from the bee brain EST sequencing project with data from sequencing and gene research projects from other organisms, primarily the fruit fly Drosophila melanogaster. The goal of Bee-ESTdb is to provide updated information on the genes of the honey bee, currently using annotation primarily from flies to suggest cellular roles, biological functions, and evolutionary relationships. The site allows searches by sequence ID, EST annotations, Gene Ontology terms, Contig ID and using BLAST. Very nice resource for those interested in comparative genomics of brain. A normalized unidirectional cDNA library was made in the laboratory of Prof. Bento Soares, University of Iowa. The library was subsequently subtracted. Over 20,000 cDNA clones were partially sequenced from the normalized and subtracted libraries at the Keck Center, resulting in 15,311 vector-trimmed, high-quality, sequences with an average read length of 494 bp. and average base-quality of 41. These sequences were assembled into 8966 putatively unique sequences, which were tested for similarity to sequences in the public databases with a variety of BLAST searches. The Clemson University Genomics Institute is the distributor of these public domain cDNA clones. For information on how to purchase an individual clone or the entire collection, please contact www.genome.clemson.edu/orders/ or generobi (at) life.uiuc.edu.

Proper citation: Honey Bee Brain EST Project (RRID:SCR_002389) Copy   

•   Source: SciCrunch Registry

http://lgsun.grc.nia.nih.gov/cDNA/cDNA.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 23,2022. Project portal housing NIA Mouse EST Project, NIA Mouse cDNA Clone Sets, a NIA Mouse Gene Index, NIA Mouse cDNA Database, and NIA Mouse Microarrays. Characteristics of NIA 15K Mouse cDNA Clone Set * ~15,000 unique cDNA clones were rearrayed among 52,374 ESTs from pre- and periimplantation embryos, E12.5 female gonad/mesonephros, and newborn ovary. * Up to 50% are derived from novel genes. * ~1.5 kb average insert size. * Clones were sequenced from 5' and 3' termini to obtain longer reads and verify sequence. Sequence information is available at this Web Site. Clone names are from H3001A01 to H3159G07. * Handling of NIA 15k cDNA Clone Set(June3, 2000) Characteristics of NIA mouse 7.4K cDNA Clone Set * ~7407 cDNA clones with no redundancy within the set or with NIA Mouse 15K. * ~1.5 kb average insert size for short insert clones and ~2.5-3.0 kb average insert size for long-insert enriched clones.. * Clones were sequenced from 5' and 3' termini to obtain longer reads and verify sequence. Sequence information is available at this Web Site. Clone names are from H4001A01 to H4079G07. * Handling of NIA mouse 7.4k cDNA Clone Set (similar to handling of NIA mouse 15K, to be updated) Individual Clones are available from ATCC and MRC geneservice, UK. To obtain Clone, search the database using either the rearrayed clone name or GenBank accession number at the Key Word Search page. Follow the link to the sequence information page for the rearrayed clone to obtain source clone ATCC number. Clicking the ATCC number will bring up the ATCC ordering page for the source clone. There is essentially no overlap between the two clone sets (7.4K and 15K) said Minoru S.H. Ko, M.D., Ph.D., head of the Developmental Genomics and Aging Section in the NIA's Laboratory of Genetics. In addition, all cDNA clones in the NIA 7.4K set were purified by single colony isolation and sequence-verified, and more than half were prepared by a new procedure that yields long full-length cDNAs (average size 3-4 kb). The NIA Mouse 15k and 7.4k Clone Set Data and Published Microarray Data are available for download. NIA Mouse Microarrays *Microarray Data Download * 60-mer Oligo Array Platform ** (A) NIA 22k Oligo Microarray Gene List (21939 gene features) ( Carter et al 2003 ) ** (B) Agilent Mouse Development Oligo Microarray Gene List ** ( Subset of Microarray (A): 20,280 gene features ) * Data Analysis Tools

Proper citation: NIA Mouse cDNA Project Home Page (RRID:SCR_001472) Copy   

•   Source: SciCrunch Registry

http://www.diabetestrialnet.org/biobank/

Provides investigators with the opportunity to obtain on-demand biological samples from selected individuals that TrialNet has developed through the longitudinal monitoring of individuals at risk for the development of type 1 diabetes within the Natural History study. Exploratory research is encouraged under this initiative. Studies must use TrialNet screened subjects, and cannot interfere with ongoing clinical trials or studies. Investigators can select the clinical characteristics needed for their study as well as the sample type and collection frequency. Although many Living Biobank studies may be implemented through cost-sharing with the TrialNet network, special sample collections and visits outside of the normal visit schedules will incur additional costs which should be covered by the approved applicant. In addition, some studies may require effort from the TrialNet coordinating center, with costs covered by the approved ancillary study. Living biobank studies will be evaluated with careful consideration for their potential impact on the objectives and performance of the TrialNet Natural History study. To protect the interests of TrialNet, each living biobank study must be reviewed and approved by the Ancillary Studies Committee before its initiation. All approved living biobank studies will be reviewed yearly to evaluate their progress, and impact on TrialNet as a whole. TrialNet welcomes the submission of living biobank studies as an adjunct to ongoing protocols.

Proper citation: Living Biobank (RRID:SCR_001510) Copy   

•   Source: SciCrunch Registry

http://www.utsouthwestern.edu/labs/acute-liver/

Clinical research network for gathering prospective data and bio-samples on acute liver failure in adults since 1998. Clinical histories and laboratory and outcome data are available. Sample types include serum, plasma, urine, DNA, and liver tissue.

Proper citation: Acute Liver Failure Study Group (RRID:SCR_001463) Copy   

•   Source: SciCrunch Registry

https://wfcc.info/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 23,2022. Collects, authenticates, maintains and distributes cultures of microorganisms and cultured cells. Its aim is to promote and support the establishment of culture collections and related services, to provide liaison and set up an information network between the collections and their users, to organize workshops and conferences, publications and newsletters and work to ensure the long term perpetuation of important collections. The WFCC (through the activities of Professor Skerman, University of Queensland, Australia, and his colleagues in the 1960's) pioneered the development of an international database on culture resources worldwide. The result is the WFCC World Data Center for Microorganisms (WDCM). This data resource is now maintained at National Institute of Genetics (NIG), Japan and has records of nearly 476 culture collections from 62 countries. The records contain data on the organization, management, services and scientific interests of the collections. Each of these records is linked to a second record containing the list of species held. The WDCM database forms an important information resource for all microbiological activity and also acts as a focus for data activities among WFCC members.

Proper citation: World Federation for Culture Collections (RRID:SCR_001974) Copy   

•   Source: SciCrunch Registry